{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:49:50Z","timestamp":1793663390798,"version":"4.5.1"},"reference-count":49,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["H79TI083343"],"award-info":[{"award-number":["H79TI083343"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA045745"],"award-info":[{"award-number":["DA045745"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA045848"],"award-info":[{"award-number":["DA045848"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Concerns have been raised that pharmacists sometimes act as barriers to patients with opioid use disorder (OUD) accessing buprenorphine treatment. The present research explores how community pharmacists\u2019 endorsement (vs non-endorsement) of stigmatizing beliefs about patients taking buprenorphine relate to intentions, comfort, and decisions regarding dispensing buprenorphine for OUD. In addition, we assessed attitudes toward risk in pharmacy practice as a novel correlate of dispensing intentions and decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A sample of 207 active community-based pharmacists practicing in the United States responded to survey items measuring stigma, risk tolerance, and intentions to dispense buprenorphine. The survey included 2 vignettes in which patients presented to the pharmacy with a prescription for buprenorphine, and respondents rated their comfort with dispensing and decisions regarding dispensing in the vignette.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Results suggest that both stigma toward patients taking buprenorphine to treat OUD and tolerance for risk in pharmacy settings are related to differences in pharmacists\u2019 intentions to and willingness to dispense buprenorphine for OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Findings support the need for interventions to reduce stigma associated with buprenorphine use among pharmacists and suggest that risk tolerance is an important determinant of pharmacists\u2019 behavior that merits further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342231215178","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T06:31:42Z","timestamp":1704349902000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8716","authenticated-orcid":false,"given":"Alysson E.","family":"Light","sequence":"first","affiliation":[{"name":"University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci C.","family":"Green","sequence":"additional","affiliation":[{"name":"Brandeis University, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paria Sanaty","family":"Zadeh","sequence":"additional","affiliation":[{"name":"American Pharmacists Association, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Burns","sequence":"additional","affiliation":[{"name":"American Pharmacists Association, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin, Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2021 national survey on drug use and health. Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration. 2022. Accessed April 19 2023. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report"},{"key":"e_1_3_3_3_2","unstructured":"Ahmad F Cisewski J Rossen L Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2023. Accessed January 11 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"e_1_3_3_4_2","volume-title":"Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP)","author":"Substance Abuse and Mental Health Services Administration","year":"2021","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP). Substance Abuse and Mental Health Services Administration; 2021."},{"key":"e_1_3_3_5_2","unstructured":"Doyle S Baaklini V. President signs bipartisan measure to improve addiction treatment. 2022. Accessed April 19 2023. https:\/\/pew.org\/3GqEHmL"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.12.070"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15314"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.04.019"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.08.017"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1900988"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/29767342.2022.2060449"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.06.008"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.01.001"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7455683"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1037\/pspp0000090"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.125.3.367"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2012.11.041"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/lsi.12092"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.04.049"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/425090"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2013.12094"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.10.027"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o2688"},{"key":"e_1_3_3_27_2","unstructured":"American Academy of Family Physicians. Stakeholders\u2019 challenges and red flag warning signs related to prescribing and dispensing controlled substances. 2016. https:\/\/www.nacds.org\/ceo\/2015\/0312\/stakeholders.pdf"},{"key":"e_1_3_3_28_2","unstructured":"Jewett C Gabler E. Opioid settlement hinders patients\u2019 access to a wide array of drugs. The New York Times. 2023. Accessed May 12 2023. https:\/\/www.nytimes.com\/2023\/03\/13\/us\/drug-limits-adhd-depression.html"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2020.12.142"},{"issue":"333","key":"e_1_3_3_30_2","first-page":"134","article-title":"Attitudes to risk taking in medical decision making among British, Dutch and Belgian general practitioners","volume":"40","author":"Grol R","year":"1990","unstructured":"Grol R, Whitfield M, De Maeseneer J, Mokkink H. Attitudes to risk taking in medical decision making among British, Dutch and Belgian general practitioners. Br J Gen Pract. 1990;40(333):134-136.","journal-title":"Br J Gen Pract"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0749-5978(91)90020-T"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2601(06)38002-1"},{"key":"e_1_3_3_33_2","unstructured":"Gallucci M. jAMM: jamovi advanced mediation models. 2020. Accessed April 19 2023. https:\/\/jamovi-amm.github.io\/index.html"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3758\/BF03193146"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.112.1.155"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.01984"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026595011371"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.5688\/ajpe8421"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/29767342.2021.2010162"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2002908"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.04.031"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000001540"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02640365"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9801800310"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1037\/apl0000596"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.06.010"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.04.016"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1006\/obhd.1996.2675"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/29767342.2020.1809605"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.94.1.18"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231215178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342231215178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231215178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:49:02Z","timestamp":1777600142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342231215178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/29767342231215178"],"URL":"https:\/\/doi.org\/10.1177\/29767342231215178","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}